A comprehensive high cost drugs dataset from the NHS in England - An OpenSAFELY-TPP Short Data Report

Wellcome Open Research

article

Caroline E. Morton¹  Krishnan Bhaskaran²  Christopher T. Rentsch²  Elizabeth Williamson²  Richard Croker¹  Seb Bacon¹  George Hickman¹  Tom Ward¹  Amelia Green¹  Louis Fisher¹  Helen J Curtis¹  John Tazare²  Rosalind M. Eggo²  Peter Inglesby¹  Jonathan Cockburn³  Helen I. McDonald²  Rohini Mathur²  Angel YS Wong²  Harriet Forbes²  John Parry³  Frank Hester³  Sam Harper³  Ian J Douglas²  Liam Smeeth²  Laurie A Tomlinson²  Charlie W Lees⁴  Stephen Evans²  Catherine Smith⁵  Sinéad M. Langan²  Amir Mehkar¹  Brian MacKenna¹  Ben Goldacre¹  Anna Rowan¹  Chris Bates³  William Hulme¹  David Evans¹  Simon Davy¹  Nicholas A Kennedy⁶  James Galloway⁸  Kathryn E Mansfield²  Katie Bechman⁸  Julian Matthewman²  Mark Yates⁸  Jeremy Brown⁸  Anna Schultze²  Sam Norton³  Alex J. Walker¹ 

[1] The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford;Electronic Health Records Research Group, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine;TPP;Centre for Genomics and Experimental Medicine, University of Edinburgh;St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust;Department of Gastroenterology, Royal Devon & Exeter NHS Foundation Trust;IBD Research Group, University of Exeter;Centre of Rheumatic Diseases, King's College London

关键词: Medications;    healthcare administration;    biosimilars;    OpenSAFELY;   

DOI  :  10.12688/wellcomeopenres.17360.1

学科分类：内科医学

来源: Wellcome

【 摘 要 】

Background: At the outset of the COVID-19 pandemic, there was no routine comprehensive hospital medicines data from the UK available to researchers. These records can be important for many analyses including the effect of certain medicines on the risk of severe COVID-19 outcomes. With the approval of NHS England, we set out to obtain data on one specific group of medicines, “high-cost drugs” (HCD) which are typically specialist medicines for the management of long-term conditions, prescribed by hospitals to patients. Additionally, we aimed to make these data available to all approved researchers in OpenSAFELY-TPP. This report is intended to support all studies carried out in OpenSAFELY-TPP, and those elsewhere, working with this dataset or similar data.Methods: Working with the North East Commissioning Support Unit and NHS Digital, we arranged for collation of a single national HCD dataset to help inform responses to the COVID-19 pandemic. The dataset was developed from payment submissions from hospitals to commissioners.Results: In the financial year (FY) 2018/19 there were 2.8 million submissions for 1.1 million unique patient IDs recorded in the HCD. The average number of submissions per patient over the year was 2.6. In FY 2019/20 there were 4.0 million submissions for 1.3 million unique patient IDs. The average number of submissions per patient over the year was 3.1. Of the 21 variables in the dataset, three are now available for analysis in OpenSafely-TPP: Financial year and month of drug being dispensed; drug name; and a description of the drug dispensed.Conclusions: We have described the process for sourcing a national HCD dataset, making these data available for COVID-19-related analysis through OpenSAFELY-TPP and provided information on the variables included in the dataset, data coverage and an initial descriptive analysis.

【 授权许可】

CC BY